Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ptc Therapeutics (PTCT) EBIT (2016 - 2025)

Ptc Therapeutics has reported EBIT over the past 14 years, most recently at -$71.3 million for Q4 2025.

  • Quarterly results put EBIT at -$71.3 million for Q4 2025, up 56.06% from a year ago — trailing twelve months through Dec 2025 was $866.9 million (up 386.52% YoY), and the annual figure for FY2025 was $866.9 million, up 386.52%.
  • EBIT for Q4 2025 was -$71.3 million at Ptc Therapeutics, down from $3.0 million in the prior quarter.
  • Over the last five years, EBIT for PTCT hit a ceiling of $970.2 million in Q1 2025 and a floor of -$209.5 million in Q2 2023.
  • Median EBIT over the past 5 years was -$85.6 million (2021), compared with a mean of -$34.8 million.
  • Biggest five-year swings in EBIT: crashed 2890.19% in 2024 and later soared 2234.57% in 2025.
  • Ptc Therapeutics' EBIT stood at -$84.7 million in 2021, then crashed by 136.45% to -$200.3 million in 2022, then surged by 102.91% to $5.8 million in 2023, then crashed by 2890.19% to -$162.4 million in 2024, then soared by 56.06% to -$71.3 million in 2025.
  • The last three reported values for EBIT were -$71.3 million (Q4 2025), $3.0 million (Q3 2025), and -$35.0 million (Q2 2025) per Business Quant data.